Department of Chest Diseases, School of Medicine, Adnam Menderes University, Aydin, Turkey.
Int J Clin Pract. 2009 Feb;63(2):275-81. doi: 10.1111/j.1742-1241.2007.01501.x. Epub 2007 Nov 15.
Decreased anabolic hormone levels are described in chronic obstructive pulmonary disease (COPD), leading to important clinical consequences. The aim of this study was to evaluate the alterations in sex hormone levels in men with COPD to compare with age-matched control subjects, the determinants of these alterations, the relationship between hypogonadism and markers of systemic inflammation [interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-alpha)] and the androgen status during an acute exacerbation of COPD.
A total of 103 COPD patients and 30 control subjects were admitted to the study. 83 stable COPD patients and 30 control subjects were evaluated as outpatients. 20 patients with COPD exacerbation were hospitalised and evaluated before discharge and after 1 month.
Testosterone and dehydroepiandrosteronesulphate (DHEAS) levels of both COPD groups were lower than that of the control group. Luteinizing hormone (LH), follicle stimulating hormone (FSH) levels were increased during exacerbation. Testosterone and DHEAS levels increased and LH decreased in follow-up measurements of COPD exacerbation group. Testosterone and DHEAS levels were lower in severe COPD [forced expiratory volume in 1 s (FEV(1)) < 50%], in patients with severe hypoxaemia (PaO(2) < 60 mmHg) and in hypercapnic patients. Circulating IL-6 and TNF-alpha concentrations were higher in both stable and exacerbation phase COPD groups than controls. There was no correlation between sex hormones and TNF-alpha or IL-6.
The alterations in sex hormone levels in COPD are particularly related to FEV(1), hypoxaemia and hypercapnia. There are significant differences in hormone levels during stable and exacerbation phases of COPD; the hormonal changes are marked during exacerbation and partially regress after 1 month when the disease is stabilised.
描述慢性阻塞性肺疾病(COPD)患者中合成代谢激素水平降低,导致重要的临床后果。本研究旨在评估 COPD 男性患者的性激素水平变化,并与年龄匹配的对照组进行比较,确定这些变化的决定因素,以及低雄激素血症与全身炎症标志物[白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)]之间的关系,并评估 COPD 急性加重期间的雄激素状态。
共纳入 103 例 COPD 患者和 30 例对照组患者。83 例稳定期 COPD 患者和 30 例对照组患者为门诊患者。20 例 COPD 加重患者住院并在出院前和出院后 1 个月进行评估。
两组 COPD 患者的睾酮和硫酸脱氢表雄酮(DHEAS)水平均低于对照组。在加重期,黄体生成素(LH)、卵泡刺激素(FSH)水平升高。在 COPD 加重组的随访测量中,睾酮和 DHEAS 水平升高,LH 水平降低。在严重 COPD [第 1 秒用力呼气量(FEV1)<50%]、严重低氧血症(PaO2<60mmHg)和高碳酸血症患者中,睾酮和 DHEAS 水平较低。在稳定期和加重期 COPD 组,循环中白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)浓度均高于对照组。性激素与 TNF-α或 IL-6 之间无相关性。
COPD 患者的性激素水平变化与 FEV1、低氧血症和高碳酸血症特别相关。在 COPD 的稳定期和加重期,激素水平存在显著差异;在加重期,激素变化明显,疾病稳定后 1 个月时部分恢复。